Inhibition of IGF-1 Signalling Enhances the Apoptotic Effect of AS602868 in Multiple Myeloma Cell Lines
Author Information
Author(s): Tagoug Ines, Sauty De Chalon Amélie, Dumontet Charles, Koritzinsky Marianne
Primary Institution: Université de Lyon, Lyon, France
Hypothesis
Can the combination of the IKK2 inhibitor AS602868 and a monoclonal antibody targeting IGF-1 receptor enhance apoptosis in multiple myeloma cell lines?
Conclusion
The combination of anti-IGF-1R antibody with AS602868 significantly increases apoptosis in multiple myeloma cell lines that express high levels of IGF-1R.
Supporting Evidence
- Anti-IGF-1R antibody enhanced the cytotoxic effect of AS602868 on RPMI8226 and LP1 cell lines.
- The combination of anti-IGF-1R with AS602868 increased the apoptotic fraction in RPMI8226 and LP1 cells.
- AS602868 was found to block the activation of NF-κB and induce apoptosis in MM cell lines.
- 30% of primary plasma cells express IGF-1R, and the combination treatment increased apoptosis in these cells.
Takeaway
This study shows that using a special drug together with an antibody can help kill cancer cells better than using either one alone.
Methodology
The study involved in vitro experiments on multiple myeloma cell lines using flow cytometry, MTT assays, and western blotting to analyze apoptosis and signaling pathways.
Limitations
The study primarily focused on specific cell lines and may not fully represent the complexity of multiple myeloma in patients.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website